Invictus Oncology is a cancer therapeutics startup based in Delhi, India, that develops oncology drug candidates for clinical trials.

This Startup Deep Dive explains what Invictus Oncology does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Invictus Oncology in Brief

• What it is: Invictus Oncology is an Indian Cancer therapeutics company based in Delhi.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• It is a Delhi-based biopharma company developing novel cancer therapeutics.
• Its platform uses supramolecular technology to design anti-cancer drugs that target tumours and modulate the tumour immune response.
• Lead molecule IO-125 is a platinum-based supramolecular therapeutic developed for triple-negative breast cancer.
• Funding: Rs 10.5 crore (about $1.88M) from Navam Capital and Aarin Capital; Ratan Tata later joined the Series A first close with an undisclosed amount.

Invictus Oncology Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Invictus Oncology?

Invictus Oncology operates in the Cancer therapeutics space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Invictus Oncology.

• It is a Delhi-based biopharma company developing novel cancer therapeutics.
• Its platform uses supramolecular technology to design anti-cancer drugs that target tumours and modulate the tumour immune response.
• Lead molecule IO-125 is a platinum-based supramolecular therapeutic developed for triple-negative breast cancer.
• It also developed a linker chemistry for antibody-drug conjugates that keeps the drug attached in blood and releases it at the tumour (published in Chemical Science, 2017).

The Origin Story of Invictus Oncology

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Shiladitya Sengupta, Raghunath Mashelkar.
• Co-founded by Shiladitya Sengupta, a Harvard Medical School faculty member, and Padma Vibhushan Raghunath Mashelkar.
• A discovery at Harvard using nanotechnology-based strategies to destroy cancer cells led to the idea of the company.
• Sengupta also founded Vyome Biosciences, which Navam and Aarin also backed.
• Founding year differs: 2011 in most profiles and a 2013 mention in one article.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Cancer therapeutics sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• May 2013: first Series A money of Rs 10.5 crore (about $1.88M) from Navam Capital and Aarin Capital (reported by one outlet with that date).
• 2015: data on IO-125 presented at the San Antonio Breast Cancer Symposium and ASCO Breast Cancer Symposium.
• February 2016: Ratan Tata invested in the first close of the Series A.
• March 2017: paper on its antibody-drug conjugate linker chemistry published in Chemical Science.

Invictus Oncology Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Series A first money, reported May 2013, Rs 10.5 crore (about $1.88M), Navam Capital and Aarin Capital.
• Series A first close, February 2016, undisclosed amount, Ratan Tata joined with Navam Capital and Aarin Capital; funds meant to take IO-125 through Phase I and file a second IND within 12-18 months.

How Does Invictus Oncology Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Drug-discovery company that aims to advance candidates through early clinical trials; commercial route (partnering or licensing) is not stated in sources read.
• Funded by venture and angel capital rather than product revenue.

The Numbers: Invictus Oncology Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• Rs 10.5 crore (about $1.88M) first funding.
• Ownership data cited by a database: investors held 48.1% and Sengupta 29.6% as of 31 March 2023.

Market Opportunity for Invictus Oncology

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Founders pitched a roughly $20 billion oncology market opportunity (company-stated, 2016).
• Mashelkar called it among the first India-based startups to pursue novel discovery and biotech innovation (company-stated).

Technology and Product at Invictus Oncology

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Supramolecular drug design platform, with IO-125 validated in multiple cancer models (company-stated).
• Novel linker chemistry for antibody-drug conjugates published in 2017.

Team and Culture at Invictus Oncology

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Shiladitya Sengupta, Harvard Medical School faculty member, co-founder.
• Raghunath Mashelkar, co-founder.
• Monideepa Roy, Director of R&D (as of 2017).

Invictus Oncology Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for Invictus Oncology

• No funding or clinical news after 2017 was found, so current status is unclear.
• Drug development at preclinical or Phase I stage carries high failure risk.
• Competitor lists come from generic databases and are not a verified competitive analysis.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Invictus Oncology Growth Outlook: What to Watch

• As of 2016-2017 reports, plans were to advance IO-125 through Phase I and file a second IND.
• Current status is unknown; no recent announcements were found.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Invictus Oncology can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Invictus Oncology Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Invictus Oncology

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Invictus Oncology.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Invictus Oncology

Studying a company in the Cancer therapeutics space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Invictus Oncology.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Invictus Oncology as a Startup

• Customer clarity: Can Invictus Oncology name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Invictus Oncology is part of India’s growing Cancer therapeutics ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Invictus Oncology FAQs: Frequently Asked Questions

What is Invictus Oncology?

Invictus Oncology is a cancer therapeutics startup based in Delhi, India, that develops oncology drug candidates for clinical trials. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Invictus Oncology?

Invictus Oncology was founded by Shiladitya Sengupta, Raghunath Mashelkar, and the company reports a founding year of 2011 (reports differ: one article says 2013).

How much funding has Invictus Oncology raised?

Rs 10.5 crore (about $1.88M) from Navam Capital and Aarin Capital; Ratan Tata later joined the Series A first close with an undisclosed amount. Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Invictus Oncology make money?

Invictus Oncology earns revenue from its Cancer therapeutics products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Invictus Oncology?

Reported rivals include Sayre Therapeutics, Zuvius Lifesciences, Cadila Pharmaceuticals, Intas. See the competitor comparison above for how they differ.

What are the main risks for Invictus Oncology?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: MOC Cancer Care — MOC Cancer Care: oncologist-founded daycare chain raised $18M in 2025 | Dawaa Dost — short profile of what is publicly known. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.